About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
PRTA - Prothena Corporation...| Previous Close | $22.60 | Open | $23.85 |
| Volume | 267.6K | Market Cap | 379.11M |
| Yield | Last Dividend |
| Prothena (NASDAQ:PRTA) Releases Quarterl... | 02/12/21 |
| Prothena (NASDAQ:PRTA) issued its quarterly earnings data on Wednesday. The biotechnology company reported ($0.77) EPS for the quarter, hitting the Th... | |
| Why Corvus Pharmaceuticals, Prothena, Co... | 02/12/21 |
| Corvus Pharmaceuticals (NASDAQ: CRVS ) shares are ??? Full story available on Benzinga.com | |
| The Daily Biotech Pulse: European Regula... | 02/12/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 12) 4D ... | |
| The Daily Biotech Pulse: DermTech Soars ... | 02/11/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11) 10X... | |
| The Daily Biotech Pulse: Lilly COVID-19 ... | 02/10/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 10) 9 M... | |
| Prothena Announces Confirmatory Phase 3 ... | 02/01/21 |
| Significant survival benefit observed in VITAL study for birtamimab-treated patients with AL amyloidosis at high risk for early mortality (Mayo Stage ... | |
| Prothena Announces Inducement Grant Unde... | 12/04/20 |
| DUBLIN, Ireland, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein??? | |
| U.S. Transthyretin Amyloidosis Treatment... | 11/17/20 |
| Industrial Growth Forecast Report U.S. Transthyretin Amyloidosis Treatment Market 2020-2027: The Global U.S. Transthyretin Amyloidosis Treatment Marke... | |
| Prothena Reports Third Quarter 2020 Fina... | 11/04/20 |
| Net cash used in operating and investing activities was $19.5 million in the third quarter and $61.4 million for the first nine months of 2020; quarte... | |
| Prothena Announces Presentations on Two ... | 11/04/20 |
| Next generation anti-A?? antibodies being developed for subcutaneous administration to improve access for patients with Alzheimer???s diseaseMulti-imm... | |
| Prothena to Report Third Quarter 2020 Fi... | 10/28/20 |
| DUBLIN, Ireland, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein??? | |
| FY2020 EPS Estimates for Prothena Co. PL... | 10/24/20 |
| Prothena Co. PLC (NASDAQ:PRTA) ??? Equities researchers at Cantor Fitzgerald cut their FY2020 EPS estimates for Prothena in a report released on Wedne... | |
| Prothena Co. PLC (NASDAQ:PRTA) Expected ... | 10/24/20 |
| Equities research analysts expect Prothena Co. PLC (NASDAQ:PRTA) to report earnings per share of ($0.68) for the current quarter, Zacks reports. Three... | |
| Prothena (NASDAQ:PRTA) Shares Gap Up on ... | 10/23/20 |
| Prothena Co. PLC (NASDAQ:PRTA) gapped up prior to trading on Wednesday after Cantor Fitzgerald raised their price target on the stock from $20.00 to $... | |
| Prothena (NASDAQ:PRTA) Shares Gap Up Fol... | 10/21/20 |
| Prothena Co. PLC (NASDAQ:PRTA) shares gapped up prior to trading on Wednesday after Cantor Fitzgerald raised their price target on the stock from $20.... | |
| The Daily Biotech Pulse: Prothena Progre... | 10/21/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 20) Ail... | |
| Cantor Fitzgerald Raises Prothena (NASDA... | 10/21/20 |
| Prothena (NASDAQ:PRTA) had its price objective raised by equities researchers at Cantor Fitzgerald from $20.00 to $24.00 in a research note issued to ... | |
| Zacks: Analysts Anticipate Prothena Co. ... | 10/21/20 |
| Equities analysts predict that Prothena Co. PLC (NASDAQ:PRTA) will report earnings per share of ($0.68) for the current fiscal quarter, Zacks Investme... | |
| Brokerages Set Prothena Co. PLC (NASDAQ:... | 10/20/20 |
| Prothena Co. PLC (NASDAQ:PRTA) has received an average recommendation of ???Hold??? from the seven brokerages that are presently covering the firm, Ma... | |
| The Week Ahead In Biotech: Decision Day ... | 09/13/20 |
| Biotech stocks continued to remain under pressure in the week ended Sept. 11, swayed by the volatility that was evident in the broader market. The wee... | |
| Prothena Announces Inducement Grant Unde... | 09/02/20 |
| DUBLIN, Ireland, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein??? | |
| Prothena Reports Second Quarter 2020 Fin... | 08/06/20 |
| Net cash used in operating and investing activities was $18.7 million in the second quarter and $41.9 million for the first six months of 2020; quarte... | |
| Prothena Announces Phase 2 PASADENA Stud... | 08/05/20 |
| Phase 2 PASADENA Part 1 study results selected as an oral Top Abstract DUBLIN, Ireland, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc??? | |
| Prothena to Report Second Quarter 2020 F... | 07/30/20 |
| DUBLIN, Ireland, July 30, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein??? | |
| Prothena Reports First Quarter 2020 Fina... | 05/06/20 |
| Net cash used in operating and investing activities was $23.2 million in the first quarter; quarter-end cash and restricted cash position of $355.4 mi... | |
| Analysts Estimate Prothena (PRTA) to Rep... | 04/28/20 |
| Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with ... | |
| Prothena (PRTA) Down 24.8% Since Last Ea... | 03/13/20 |
| Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | |
| Prothena (PRTA) Q4 Loss Narrower Than Ex... | 02/13/20 |
| Prothena (PRTA) reports a narrower-than-expected Q4 loss, while revenues surpass estimates. | |
| AT&T : Thinking about buying stock in Ba... | 12/23/19 |
| NEW YORK, Dec. 23, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BAC, LYFT, PRTA, RAD, and T. To see how InvestorsObser... | |
| Why Is Prothena (PRTA) Up 36.1% Since La... | 12/05/19 |
| Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | |
| Buy rating | 02/12/21 |
| Jefferies upgrades from Hold to Buy rating and raises Price Target from $15.00 to $30.00 | |
| Buy rating | 02/04/21 |
| HC Wainwright & Co. maintains Buy rating and raises Price Target from $22.00 to $33.00 | |
| Buy rating | 02/02/21 |
| BTIG upgrades from Neutral to Buy rating and announces Price Target of $29.00 | |
| Strong Buy rating | 02/02/21 |
| Oppenheimer maintains Outperform rating and raises Price Target from $25.00 to $35.00 | |
| Buy rating | 12/07/20 |
| HC Wainwright & Co. initiates coverage with Buy rating and announces Price Target of $22.00 | |
| Date | 2021-02-11 (AMC) | Est. (EPS/Rev.) | ($0.77)/ 170K |
| Actual (EPS/Rev.) | $-0.77/ $360.00 K | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| LavaPit | Steve Pitkin | 57.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
